Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	114.54	105.9	-56.42	-55.19	872.13	-199.43
Depreciation & Amortization	5.7	5.64	6.12	6.15	7.71	8.59
Stock-Based Compensation	18.1	18.48	21.39	25.37	39.73	62.06
Other Adjustments	-13.94	-11.94	-2.99	5.01	-1,149	-39.53
Change in Receivables	49.77	-27.1	-0.97	-0.69	-2.72	1.8
Changes in Accounts Payable	-1.31	0.33	0.75	0.01	-1.61	-3.53
Changes in Accrued Expenses	0.66	4.01	1.47	-7.1	-15.33	-37.23
Changes in Income Taxes Payable	-1.53	10.48	9.91	1.1	63.95	-0.19
Changes in Unearned Revenue	-	-	-	-0.22	-0.19	-11.46
Changes in Other Operating Activities	62.48	132.75	9.2	-1.45	-1.75	11.06
Operating Cash Flow	268.78	238.54	-11.54	-27	-186.99	-207.86
Operating Cash Flow Growth	726.36%	-	-	-	-	-
Capital Expenditures	-0.03	-0.04	-0.33	-2.49	-0.57	-3.41
Sale of Property, Plant & Equipment	-	-	-	1.51	1.87	0.01
Proceeds from Sale of Intangible Assets	-	-	-	-	2.71	-
Purchases of Investments	-289.66	-248.22	-143.04	-134.53	-103.15	-158.31
Proceeds from Sale of Investments	206.38	142.98	155.65	102.81	158.02	286.2
Investing Cash Flow	-83.32	-105.28	12.28	-32.7	1,154	124.49
Long-Term Debt Issued	-	-	-	-	24.46	-
Long-Term Debt Repaid	-	-	-	-	-631.6	-10.73
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-607.14	-10.73
Issuance of Common Stock	0.73	0.79	0.61	0.62	0.8	111.65
Repurchase of Common Stock	-8.98	-4.03	-3.1	-199.55	-132.28	-9.06
Net Common Stock Issued (Repurchased)	-8.25	-3.25	-2.5	-198.93	-131.48	102.59
Financing Cash Flow	-7.97	-3.25	-2.5	-198.93	-758.81	91.86
Net Cash Flow	177.49	130.01	-1.75	-258.63	208.21	8.5
Free Cash Flow	268.76	238.5	-11.87	-29.49	-187.56	-211.26
Free Cash Flow Growth	12.69%	-	-	-	-	-
FCF Margin	244.82%	221.93%	-18.43%	-51.35%	-365.29%	-381.96%
Free Cash Flow Per Share	5.20	4.63	-0.24	-0.53	-2.55	-3.04
Levered Free Cash Flow	180.51	259.06	-29.31	-59.18	317.2	-246.33
Unlevered Free Cash Flow	66.97	150.22	-32.26	-66.76	-217.08	-293.81

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q